Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Lantheus Holdings, Inc. develops, manufactures, sells, and distributes diagnostic medical imaging agents and products. The Company offers imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. Lantheus Holdings serves customers worldwide.
Website: lantheus.com



Growth: Good revenue growth rate 22.9%, there is slowdown compared to average historical growth rates 64.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +39.1%. On average the margin is improving unsteadily. Gross margin is high, +65.4%. In the last quarter the company beat the estimated EPS, +16.7%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.30 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 287.1% higher than minimum and 24.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.1x by EV / Sales multiple , the company can be 65.0% undervalued

Insiders: For the last 3 months insiders sold company shares on $10.2 mln (-0.232% of cap.)

Key Financials (Download financials)

Ticker: LNTH  postmarket  75.76  (+0.3%)
Share price, USD:  (-3.4%)75.53
year average price 70.26  


year start price 94.06 2023-05-07

max close price 99.65 2023-05-12

min close price 51.07 2024-01-24

current price 75.53 2024-05-06
Common stocks: 68 757 000

Dividend Yield:  0.0%
FCF Yield LTM: 4.7%
EV / LTM EBITDA: 9.4x
EV / EBITDA annualized: 10.6x
Last revenue growth (y/y):  22.9%
Last growth of EBITDA (y/y):  > 200.0%
Historical revenue growth:  64.0%
Historical growth of EBITDA:  52.5%
EV / Sales: 3.7x
Margin (EBITDA LTM / Revenue): 39.1%
Fundamental value created in LTM:
Market Cap ($m): 5 193
Net Debt ($m): -155
EV (Enterprise Value): 5 038
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-03Zacks Investment Research

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

2024-05-02Seeking Alpha

Lantheus Holdings, Inc. (LNTH) Q1 2024 Earnings Call Transcript

2024-05-02Zacks Investment Research

Lantheus Holdings (LNTH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

2024-05-02Zacks Investment Research

Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates

2024-04-30Zacks Investment Research

Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now

2024-04-26Zacks Investment Research

Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today

2024-04-26Zacks Investment Research

Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings

2024-04-24Zacks Investment Research

Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know

2024-04-19Zacks Investment Research

Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?

2024-04-15Zacks Investment Research

Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LNTH LNTH LNTH LNTH LNTH LNTH LNTH
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-11-03
acceptedDate 2024-05-02 07:52:51 2024-02-22 07:49:58 2023-11-02 07:51:40 2023-08-03 07:46:55 2023-05-04 07:52:31 2023-02-23 07:48:43 2022-11-03 07:51:06
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 370M 354M 320M 322M 301M 263M 239M
costOfRevenue 118M 124M 120M 119M 224M 96M 92M
grossProfit 252M 230M 200M 203M 77M 167M 147M
grossProfitRatio 0.681 0.649 0.625 0.630 0.256 0.635 0.616
researchAndDevelopmentExpenses 48M 17M 14M 16M 31M 272M 13M
generalAndAdministrativeExpenses 48M 40M 36M 26M 23M 40M 24M
sellingAndMarketingExpenses 46M 35M 37M 36M 33M 27M 25M
sellingGeneralAndAdministrativeExpenses 93M 76M 73M 63M 56M 67M 49M
otherExpenses -10M -1000.000 1000.000 -1000.000 3M -1M 0
operatingExpenses 151M 92M 88M 79M 86M 339M 62M
costAndExpenses 270M 217M 208M 198M 310M 435M 154M
interestIncome 0 8M 5M 4M 4M 2M 504 000
interestExpense 5M 5M 5M 5M 5M 3M 2M
depreciationAndAmortization 6M 15M 15M 16M 3M -1M 13M
ebitda 107M 160M 132M 144M -6M -173M 98M
ebitdaratio 0.288 0.452 0.411 0.447 -0.020 -0.658 0.411
operatingIncome 100M 137M 112M 124M -9M -172M 86M
operatingIncomeRatio 0.271 0.388 0.351 0.386 -0.031 -0.652 0.358
totalOtherIncomeExpensesNet 71M -2M 48M 455 000 -2M -5M -3M
incomeBeforeTax 171M 138M 160M 124M -11M -176M 83M
incomeBeforeTaxRatio 0.463 0.391 0.500 0.384 -0.037 -0.670 0.347
incomeTaxExpense 40M 35M 28M 30M -8M -57M 22M
netIncome 131M 103M 132M 94M -3M -119M 61M
netIncomeRatio 0.354 0.292 0.412 0.293 -0.009 -0.453 0.256
eps 1.910 1.510 1.930 1.380 -0.041 -1.740 0.890
epsdiluted 1.870 1.470 1.880 1.330 -0.041 -1.740 0.860
weightedAverageShsOut 69M 68M 68M 68M 68M 69M 69M
weightedAverageShsOutDil 70M 70M 70M 71M 68M 69M 71M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LNTH LNTH LNTH LNTH LNTH LNTH LNTH
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-11-03
acceptedDate 2024-05-02 07:52:51 2024-02-22 07:49:58 2023-11-02 07:51:40 2023-08-03 07:46:55 2023-05-04 07:52:31 2023-02-23 07:48:43 2022-11-03 07:51:06
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 718M 714M 614M 414M 471M 416M 257M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 718M 714M 614M 414M 471M 416M 257M
netReceivables 337M 284M 259M 256M 242M 213M 197M
inventory 70M 64M 56M 52M 42M 35M 35M
otherCurrentAssets 23M 246 000 11M 23M 11M 13M 13M
totalCurrentAssets 1 149M 1 086M 948M 752M 773M 678M 502M
propertyPlantEquipmentNet 150M 192M 140M 130M 127M 122M 121M
goodwill 61M 61M 61M 61M 61M 61M 61M
intangibleAssets 142M 152M 163M 221M 220M 315M 324M
goodwillAndIntangibleAssets 203M 213M 224M 282M 281M 376M 385M
longTermInvestments 139M 2M 2M 0 0 0 0
taxAssets 139M 150M 152M 134M 134M 111M 47M
otherNonCurrentAssets 51M 8M 55M 39M 34M 34M 42M
totalNonCurrentAssets 683M 565M 573M 586M 576M 644M 594M
otherAssets 0 0 0 0 0 0 0
totalAssets 1 831M 1 651M 1 522M 1 338M 1 349M 1 321M 1 096M
accountPayables 38M 41M 37M 39M 31M 21M 30M
shortTermDebt 734 000 823 000 703 000 384 000 422 000 354 000 15M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 130M 116M 104M 0 0 0
otherCurrentLiabilities 199M 15M 23M 11M 245M 227M 190M
totalCurrentLiabilities 237M 187M 177M 154M 276M 248M 236M
longTermDebt 562M 616M 615M 590M 559M 558M 167M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 86M 32M 31M 41M 69M 69M 176M
totalNonCurrentLiabilities 649M 648M 646M 631M 627M 626M 222M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 54M 54M 31M 25M 25M 15M
totalLiabilities 886M 835M 823M 785M 904M 874M 458M
preferredStock 0 0 0 0 0 0 0
commonStock 706 000 699 000 698 000 698 000 696 000 689 000 688 000
retainedEarnings 265M 134M 30M -102M -196M -193M -74M
accumulatedOtherComprehensiveIncomeLoss -1M -1M -1M -952 000 -1M -1M 3M
othertotalStockholdersEquity 681M 683M 669M 655M 642M 641M 708M
totalStockholdersEquity 946M 816M 699M 553M 446M 447M 638M
totalEquity 946M 816M 699M 553M 446M 447M 638M
totalLiabilitiesAndStockholdersEquity 1 831M 1 651M 1 522M 1 338M 1 349M 1 321M 1 096M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 831M 1 651M 1 522M 1 338M 1 349M 1 321M 1 096M
totalInvestments 139M 2M 2M 0 0 0 0
totalDebt 563M 617M 616M 591M 559M 558M 183M
netDebt -155M -97M 2M 177M 88M 142M -74M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol LNTH LNTH LNTH LNTH LNTH LNTH LNTH
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-02 2024-02-22 2023-11-02 2023-08-03 2023-05-04 2023-02-23 2022-11-03
acceptedDate 2024-05-02 07:52:51 2024-02-22 07:49:58 2023-11-02 07:51:40 2023-08-03 07:46:55 2023-05-04 07:52:31 2023-02-23 07:48:43 2022-11-03 07:51:06
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 131M 103M 132M 94M -3M -119M 61M
depreciationAndAmortization 15M 15M 15M 16M 15M 12M 12M
deferredIncomeTax 11M 2M -18M -3M -36M -66M 8M
stockBasedCompensation 0 14M 14M 13M 10M 8M 8M
changeInWorkingCapital 0 -28M 22M -155M -11M 3M 2M
accountsReceivables -55M -26M -4M -14M -25M -16M -11M
inventory -8M -10M -7M -12M -7M -3M -3M
accountsPayables -3M 5M -2M 7M 7M -8M 9M
otherWorkingCapital 0 3M 35M -136M 25M 30M 7M
otherNonCashItems 0 6M -48M 3M 134M 267M 2M
netCashProvidedByOperatingActivities 127M 112M 117M -32M 109M 105M 94M
investmentsInPropertyPlantAndEquipment -8M -12M -15M -11M -9M -5M -6M
acquisitionsNet 0 45M 0 0 0 0 0
purchasesOfInvestments -78M 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites -20M -45M 98M -10M -35M -260M 0
netCashUsedForInvestingActivites -107M -12M 83M -21M -45M -265M -6M
debtRepayment 0 -32 000 -157 000 -231 000 -297 000 -167M -3M
commonStockIssued 2M 354 000 993 000 0 940 000 0 798 000
commonStockRepurchased 0 -773 000 -1 000 000 0 0 -75M 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -19M -772 000 1M -4M -9M 560M -85 000
netCashUsedProvidedByFinancingActivities -17M -450 000 108 000 -4M -9M 318M -2M
effectOfForexChangesOnCash 770 000 -232 000 0 237 000 -98 000 -69 000 -247 000
netChangeInCash 5M 100M 200M -57M 55M 158M 85M
cashAtEndOfPeriod 720M 715M 616M 416M 472M 417M 259M
cashAtBeginningOfPeriod 715M 616M 416M 472M 417M 259M 174M
operatingCashFlow 127M 112M 117M -32M 109M 105M 94M
capitalExpenditure -8M -12M -15M -11M -9M -5M -6M
freeCashFlow 119M 100M 102M -43M 99M 101M 87M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-04-29 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 11:00 ET
Lantheus Reports First Quarter 2024 Financial Results
2024-04-18 12:00 ET
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
2024-03-05 13:30 ET
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
2024-03-04 13:30 ET
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
2024-02-28 13:30 ET
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
2024-02-26 13:30 ET
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-22 12:00 ET
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 13:30 ET
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
2024-02-08 13:00 ET
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
2024-01-23 12:45 ET
Lantheus Announces CEO Succession Plan
2024-01-11 13:00 ET
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
2024-01-09 13:00 ET
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
2024-01-09 12:55 ET
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
2024-01-03 13:30 ET
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 12:30 ET
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
2023-11-08 13:00 ET
Lantheus to Present at the Jefferies London Healthcare Conference
2023-11-02 11:00 ET
Lantheus Reports Third Quarter 2023 Financial Results
2023-10-19 12:00 ET
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time
2023-09-01 12:30 ET
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
2023-08-31 12:00 ET
Lantheus to Present at the Wells Fargo Healthcare Conference
2023-08-03 11:10 ET
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
2023-08-03 11:00 ET
Lantheus Reports Second Quarter 2023 Financial Results
2023-07-20 12:30 ET
Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
2023-06-12 12:30 ET
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
2023-06-01 12:30 ET
Lantheus to Present at the Jefferies Healthcare Conference
2023-05-23 12:30 ET
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
2023-05-04 11:00 ET
Lantheus Reports First Quarter 2023 Financial Results
2023-04-24 11:30 ET
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
2023-04-24 11:30 ET
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
2023-04-20 12:00 ET
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
2023-03-27 12:00 ET
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
2023-03-17 12:35 ET
Lantheus Announces Two Key Executive Promotions
2023-02-23 12:00 ET
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-16 13:30 ET
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
2023-02-09 13:00 ET
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
2023-02-08 13:30 ET
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
2023-02-06 21:03 ET
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
2023-01-12 13:30 ET
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
2023-01-04 13:30 ET
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
2022-12-20 13:30 ET
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
2022-12-20 13:30 ET
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
2022-12-12 13:00 ET
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
2022-12-06 12:45 ET
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
2022-12-05 12:00 ET
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
2022-11-29 13:00 ET
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
2022-11-28 13:00 ET
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
2022-11-14 12:00 ET
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
2022-11-09 13:30 ET
Lantheus to Present at the Jefferies London Healthcare Conference
2022-11-03 11:00 ET
Lantheus Reports Third Quarter 2022 Financial Results
2022-10-20 12:30 ET
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
2022-10-17 13:14 ET
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
2022-10-06 22:59 ET
Targa Resources Set to Join S&P 500; Lantheus Holdings to Join S&P MidCap 400; Payoneer Global to Join S&P SmallCap 600
2022-09-13 12:06 ET
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
2022-09-01 12:30 ET
Lantheus to Present at the Wells Fargo Healthcare Conference
2022-08-04 11:00 ET
Lantheus Reports Second Quarter 2022 Financial Results
2022-07-21 12:00 ET
Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time
2022-06-15 13:00 ET
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
2022-06-13 12:00 ET
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
2022-06-13 11:45 ET
Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
2022-06-02 12:30 ET
Lantheus to Present at the Jefferies Healthcare Conference
2022-05-26 12:00 ET
Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
2022-05-16 20:30 ET
Lantheus Hosts Inaugural Investor Day
2022-05-16 12:00 ET
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
2022-05-13 12:00 ET
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
2022-05-11 12:00 ET
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
2022-05-10 12:30 ET
Lantheus to Present at the UBS Global Healthcare Conference
2022-04-29 11:07 ET
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
2022-04-15 12:30 ET
Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time
2022-04-04 12:00 ET
Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer
2022-03-29 12:00 ET
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
2022-03-08 13:30 ET
Lantheus Holdings to Present at the Barclays Global Healthcare Conference
2022-03-03 21:30 ET
Lantheus to Host Inaugural Investor Day
2022-03-01 21:05 ET
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
2022-02-24 12:30 ET
Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (Piflufolastat F18)
2022-02-24 12:00 ET
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-23 13:00 ET
Lantheus Receives U.S. FDA Approval of New Manufacturing Facility
2022-02-10 22:33 ET
Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
2022-02-10 13:30 ET
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time
2022-01-27 13:30 ET
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
2021-12-01 13:30 ET
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
2021-11-29 13:30 ET
Lantheus Announces PYLARIFY AI™ is Now Available
2021-11-22 13:30 ET
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
2021-11-17 13:30 ET
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
2021-11-16 21:30 ET
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-04 11:00 ET
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
2021-10-28 20:30 ET
Lantheus Holdings to Present at Upcoming Investor Conferences
2021-10-21 12:00 ET
Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time
2021-09-13 12:00 ET
Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer
2021-09-13 11:30 ET
Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment
2021-09-10 12:30 ET
Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting
2021-09-02 12:00 ET
Lantheus Holdings to Present at Upcoming Investor Conferences
2021-07-29 22:25 ET
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
2021-07-28 11:00 ET
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
2021-07-14 12:00 ET
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
2021-06-14 12:30 ET
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
2021-05-27 11:00 ET
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
2021-05-21 12:30 ET
Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
2021-05-20 12:30 ET
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
2021-05-04 11:00 ET
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
2021-05-03 12:30 ET
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
2021-04-30 12:30 ET
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
2021-04-20 12:30 ET
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
2021-04-07 12:30 ET
Lantheus Expands R&D Leadership Team with Key New Hires
2021-04-01 12:30 ET
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
2021-03-30 12:29 ET
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
2021-03-22 12:30 ET
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
2021-03-01 13:30 ET
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
2021-02-25 21:01 ET
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-12 13:30 ET
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2021-02-11 21:30 ET
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
2021-02-04 13:30 ET
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
2021-01-12 13:30 ET
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
2020-12-09 19:19 ET
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
2020-12-09 13:30 ET
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
2020-12-03 12:00 ET
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
2020-11-24 13:00 ET
Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
2020-11-18 21:01 ET
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
2020-11-13 13:30 ET
Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform
2020-11-09 21:30 ET
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
2020-11-05 12:00 ET
Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results
2020-11-04 13:00 ET
Lantheus Holdings to Present at November 2020 Investor Conferences
2020-10-29 12:30 ET
Lantheus Enters into Strategic Collaboration with Insightec for Use of Microbubbles in Combination with MR-Guided Focused Ultrasound for Treatment of Glioblastoma and Neurodegenerative Conditions
2020-10-22 11:30 ET
Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time
2020-10-08 12:25 ET
Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress
2020-09-30 12:00 ET
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
2020-09-03 12:00 ET
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
2020-08-12 12:00 ET
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
2020-07-30 11:00 ET
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results
2020-07-23 12:00 ET
Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time
2020-07-01 12:00 ET
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
2020-06-22 11:00 ET
Lantheus Completes Merger with Progenics
2020-06-16 20:05 ET
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
2020-06-16 12:30 ET
Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference
2020-05-20 20:30 ET
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
2020-05-05 20:30 ET
Lantheus Holdings to Present at the UBS Virtual Global Healthcare Conference
2020-04-30 11:00 ET
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
2020-04-16 12:30 ET
Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time
2020-04-14 13:00 ET
ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics
2020-04-09 12:30 ET
Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance
2020-04-06 12:30 ET
Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually
2020-04-02 12:30 ET
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
2020-02-25 12:00 ET
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-20 16:30 ET
Lantheus and Progenics Agree to Amended Transaction Terms
2020-02-18 14:00 ET
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-18 13:30 ET
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time
2020-02-03 13:30 ET
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
2020-01-27 13:30 ET
Lantheus Holdings Announces Senior Leadership Appointment
2020-01-13 13:30 ET
Lantheus Holdings Announces Senior Leadership Appointment
2019-12-09 13:00 ET
Lantheus Enters into Strategic Collaboration with CarThera for Use of Microbubbles in Combination with SonoCloud® System for Treatment of Glioblastoma
2019-11-21 21:05 ET
Lantheus Holdings to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-07 13:12 ET
Lantheus Releases Comprehensive Strategic Plan for Progenics
2019-10-31 11:00 ET
Lantheus Holdings, Inc. Reports Third Quarter 2019 Financial Results
2019-10-29 20:30 ET
Lantheus Holdings to Present at the Credit Suisse 28th Annual Healthcare Conference
2019-10-17 20:05 ET
Lantheus Holdings to Host Third Quarter 2019 Earnings Conference Call on October 31, 2019 at 8:00 a.m. Eastern Time
2019-10-04 22:14 ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.
2019-10-02 18:25 ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc.
2019-04-03 20:39 ET
SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
2019-02-12 12:50 ET
Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

SEC forms

Show financial reports only

SEC form 10
2024-05-02 07:52 ET
Lantheus reported for 2024 q1
SEC form 8
2024-05-02 07:46 ET
Lantheus published news for 2024 q1
SEC form 8
2024-05-02 07:46 ET
Lantheus reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Lantheus published news for 2024 q1
SEC form 10
2024-02-22 07:49 ET
Lantheus published news for 2023 q4
SEC form 8
2024-02-22 07:47 ET
Lantheus published news for 2023 q4
SEC form 8
2024-02-22 07:47 ET
Lantheus reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Lantheus published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Lantheus published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Lantheus published news for 2023 q4
SEC form 10
2023-11-02 07:51 ET
Lantheus reported for 2023 q3
SEC form 8
2023-11-02 07:44 ET
Lantheus published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Lantheus published news for 2023 q3
SEC form 10
2023-08-03 07:46 ET
Lantheus reported for 2023 q2
SEC form 6
2023-08-03 07:40 ET
Lantheus published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Lantheus published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Lantheus published news for 2023 q2
SEC form 8
2023-05-04 00:00 ET
Lantheus published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Lantheus published news for 2023 q1
SEC form 6
2023-03-17 21:15 ET
Lantheus published news for 2022 q4
SEC form 6
2023-03-17 08:46 ET
Lantheus published news for 2022 q4
SEC form 10
2023-02-23 07:48 ET
Lantheus reported for 2022 q4
SEC form 6
2023-02-23 07:45 ET
Lantheus published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Lantheus reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Lantheus reported for 2022 q4
SEC form 6
2023-02-06 16:16 ET
Lantheus published news for 2022 q4
SEC form 6
2023-01-11 09:03 ET
Lantheus published news for 2022 q4
SEC form 6
2023-01-10 17:00 ET
Lantheus published news for 2022 q4
SEC form 6
2022-12-28 16:06 ET
Lantheus published news for 2022 q3
SEC form 6
2022-12-20 08:36 ET
Lantheus published news for 2022 q3
SEC form 6
2022-12-08 16:58 ET
Lantheus published news for 2022 q3
SEC form 6
2022-12-06 08:13 ET
Lantheus published news for 2022 q3
SEC form 6
2022-12-05 07:09 ET
Lantheus published news for 2022 q3
SEC form 6
2022-11-14 07:29 ET
Lantheus published news for 2022 q3
SEC form 10
2022-11-03 07:51 ET
Lantheus reported for 2022 q3
SEC form 6
2022-11-03 07:48 ET
Lantheus published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Lantheus reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Lantheus reported for 2022 q3
SEC form 10
2022-08-04 07:57 ET
Lantheus reported for 2022 q2
SEC form 6
2022-08-04 07:52 ET
Lantheus published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Lantheus reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Lantheus reported for 2022 q2
SEC form 6
2022-06-15 09:06 ET
Lantheus published news for 2022 q1
SEC form 6
2022-05-17 08:41 ET
Lantheus published news for 2022 q1
SEC form 6
2022-05-02 16:34 ET
Lantheus published news for 2022 q1
SEC form 10
2022-04-29 07:48 ET
Lantheus reported for 2022 q1
SEC form 6
2022-04-29 07:45 ET
Lantheus published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Lantheus reported for 2022 q1
SEC form 8
2022-04-29 00:00 ET
Lantheus reported for 2022 q1
SEC form 6
2022-03-18 08:00 ET
Lantheus published news for 2021 q4
SEC form 6
2022-03-03 17:02 ET
Lantheus published news for 2021 q4
SEC form 6
2022-03-01 16:11 ET
Lantheus published news for 2021 q4
SEC form 10
2022-02-24 08:07 ET
Lantheus published news for 2021 q4
SEC form 6
2022-02-24 08:05 ET
Lantheus published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Lantheus published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Lantheus published news for 2021 q4
SEC form 6
2021-12-27 16:30 ET
Lantheus published news for 2021 q3
SEC form 6
2021-12-17 16:30 ET
Lantheus published news for 2021 q3
SEC form 10
2021-11-04 07:51 ET
Lantheus published news for 2021 q3
SEC form 6
2021-11-04 07:38 ET
Lantheus published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Lantheus published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Lantheus published news for 2021 q3
SEC form 6
2021-10-14 16:06 ET
Lantheus published news for 2021 q3
SEC form 6
2021-08-02 16:30 ET
Lantheus published news for 2021 q2
SEC form 10
2021-07-28 07:51 ET
Lantheus published news for 2021 q2
SEC form 6
2021-07-28 07:44 ET
Lantheus published news for 2021 q2
SEC form 10
2021-07-28 00:00 ET
Lantheus published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Lantheus published news for 2021 q2
SEC form 6
2021-07-23 10:09 ET
Lantheus published news for 2021 q2
SEC form 6
2021-05-27 07:06 ET
Lantheus published news for 2021 q1
SEC form 6
2021-05-10 16:30 ET
Lantheus published news for 2021 q1
SEC form 6
2021-05-10 16:30 ET
Lantheus published news for 2021 q1
SEC form 6
2021-05-10 16:30 ET
Lantheus published news for 2021 q1
SEC form 10
2021-05-04 07:44 ET
Lantheus published news for 2021 q1
SEC form 6
2021-05-04 07:38 ET
Lantheus published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Lantheus published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Lantheus published news for 2021 q1
SEC form 6
2021-04-29 16:31 ET
Lantheus published news for 2021 q1
SEC form 6
2021-04-01 08:42 ET
Lantheus published news for 2021 q1
SEC form 6
2021-03-18 16:54 ET
Lantheus published news for 2020 q4
SEC form 6
2021-03-04 20:11 ET
Lantheus published news for 2020 q4
SEC form 10
2021-02-25 17:23 ET
Lantheus published news for 2020 q4
SEC form 6
2021-02-25 16:08 ET
Lantheus published news for 2020 q4
SEC form 6
2021-02-01 07:00 ET
Lantheus published news for 2020 q4
SEC form 6
2020-12-09 15:28 ET
Lantheus published news for 2020 q3
SEC form 6
2020-12-03 07:06 ET
Lantheus published news for 2020 q3
SEC form 6
2020-11-18 16:19 ET
Lantheus published news for 2020 q3
SEC form 10
2020-11-05 16:08 ET
Lantheus published news for 2020 q3
SEC form 6
2020-11-05 07:45 ET
Lantheus published news for 2020 q3
SEC form 6
2020-10-05 16:30 ET
Lantheus published news for 2020 q3
SEC form 6
2020-09-30 08:15 ET
Lantheus published news for 2020 q2